- AU$414.84m
- AU$257.27m
- AU$0.12m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 2.41 | ||
| Price to Tang. Book | 2.52 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7,703.68 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -31.66% | ||
| Return on Equity | -30.45% | ||
| Operating Margin | -101775.02% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 7.77 | 0.31 | 0.25 | 0.19 | 0.12 | 4.23 | 4.67 | -54.35% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.
Directors
- Russell Howard NEC
- Marc Voigt CEO
- Pete Meyers NVC
- Deanne Miller COO
- Frederic Triebel CSO
- Indira Naidu SEC
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- May 21st, 1987
- Public Since
- June 23rd, 1988
- No. of Shareholders
- 13,566
- No. of Employees
- 19
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 1,455,589,575
- Address
- Plaza Building, L 12 95 Pitt St, SYDNEY, NSW 2000
- Web
- https://www.immutep.com/
- Phone
- +61 283157003
- Contact
- Catherine Strong
- Auditors
- PricewaterhouseCoopers
Upcoming Events for IMM
Similar to IMM
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Immutep share price?
As of Today at 20:16 UTC, shares in Immutep are trading at AU$0.29. This share price information is delayed by 15 minutes.
How has the Immutep share price performed this year?
Shares in Immutep last closed at AU$0.29 and the price had moved by -25.29% over the past 365 days. In terms of relative price strength the Immutep share price has underperformed the ASX All Ordinaries Index by -26.08% over the past year.
What are the analyst and broker recommendations for Immutep?
The overall consensus recommendation for Immutep is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Immutep dividend yield?
Immutep does not currently pay a dividend.
Does Immutep pay a dividend?
Immutep does not currently pay a dividend.
When does Immutep next pay dividends?
Immutep does not currently pay a dividend.
How do I buy Immutep shares?
To buy shares in Immutep you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Immutep?
As of the previous close price of AU$0.29, shares in Immutep had a market capitalisation of AU$414.84m.
Where are Immutep shares listed?
Here are the trading details for Immutep:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: IMM
What kind of share is Immutep?
Based on an overall assessment of its quality, value and momentum Immutep is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Immutep share price forecast for 2025?
The analyst consensus target price for shares in Immutep is AU$1.15. That is 303.51% above the last closing price of AU$0.29.
Analysts covering Immutep currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.04 for the next financial year.
Find out moreWhat is the trend in the Immutep share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Immutep. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -13.97%.
As of the last closing price of AU$0.29, shares in Immutep were trading -13.51% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Immutep PE Ratio?
The Immutep PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.29.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Immutep?
Immutep's management team is headed by:
- Russell Howard - NEC
- Marc Voigt - CEO
- Pete Meyers - NVC
- Deanne Miller - COO
- Frederic Triebel - CSO
- Indira Naidu - SEC